Search research articles
Contact Us
Filters
Showing results (91-100 of 125) with videos related to
Page
of 13
Sort By:
Pigment Cell & Melanoma Research
|
October 7, 2023
Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA)
Alexander Z Wei, Lanyi N Chen, Marlana Orloff, et al.
Cancer Discovery
|
December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Ryan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2025
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma
Elizabeth M Burton, Denái R Milton, Michael T Tetzlaff, et al.
Cancer Discovery
|
November 12, 2021
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Kenneth F Grossmann, Megan Othus, Sapna P Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 29, 2020
Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma
Lauren E Haydu, Serigne N Lo, Jennifer L McQuade, et al.
Oncoimmunology
|
May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
Zachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Nature Medicine
|
August 17, 2023
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
Ari VanderWalde, Shay L Bellasea, Kari L Kendra, et al.
JAMA Oncology
|
April 29, 2016
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial
Guo Chen, Jennifer L McQuade, David J Panka, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 3, 2026
Translating ctDNA into cutaneous melanoma care: An international expert survey
Glenn Geidel, Nathan Fekade, Katharina Raabe, et al.
Nature Communications
|
April 13, 2022
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Sang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 125) with videos related to
Sort By:
Page
of 13
Pigment Cell & Melanoma Research
|
October 7, 2023
Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA)
Alexander Z Wei, Lanyi N Chen, Marlana Orloff, et al.
Cancer Discovery
|
December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Ryan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2025
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma
Elizabeth M Burton, Denái R Milton, Michael T Tetzlaff, et al.
Cancer Discovery
|
November 12, 2021
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Kenneth F Grossmann, Megan Othus, Sapna P Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 29, 2020
Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma
Lauren E Haydu, Serigne N Lo, Jennifer L McQuade, et al.
Oncoimmunology
|
May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
Zachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Nature Medicine
|
August 17, 2023
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
Ari VanderWalde, Shay L Bellasea, Kari L Kendra, et al.
JAMA Oncology
|
April 29, 2016
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial
Guo Chen, Jennifer L McQuade, David J Panka, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 3, 2026
Translating ctDNA into cutaneous melanoma care: An international expert survey
Glenn Geidel, Nathan Fekade, Katharina Raabe, et al.
Nature Communications
|
April 13, 2022
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Sang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Page
of 13